RGFP966, a specific HDAC3 enzymatic inhibitor, significantly reduced diabetic cardiomyopathy (DCM), as evidenced by reduced diabetes-induced cardiac dysfunction, hypertrophy, and fibrosis and decreased cardiac oxidative stress, inflammation, and insulin resistance (Xu et al., 2017). This evidence concerns the gene HDAC3 and diabetes mellitus.